Skip to main content
. Author manuscript; available in PMC: 2025 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2024 Jul 1;96(3):259–269. doi: 10.1097/QAI.0000000000003440

Table 2:

Female Participant Outcomes

Variable Level Estimate (95% CI) P-value
Study group Intervention −0.003 (−0.072, 0.065) 0.93
Age at enrollment (years) 0.002 (−0.001, 0.005) 0.12
Education None −0.069 (−0.132, −0.006) 0.032
Some-completed primary −0.058 (−0.110, −0.005) 0.031
Marital status Single −0.002 (−0.055, 0.051) 0.93
Common law/live together 0.056 (0.007, 0.106) 0.025
ART Regimen (enrollment) DTG 0.075 (0.033, 0.116) <0.001
Depression score −0.003 (−0.007, 0.000) 0.067
HIV Knowledge score 0.002 (−0.002, 0.006) 0.45
HIV Stigma score −0.000 (−0.002, 0.001) 0.67

Reference levels: Study group (control); Education (some secondary or beyond); Marital status (married); ART regimen (other).

ART = Antiretroviral therapy; DTG = Dolutegravir.